POSTMENOPAUSAL HRT AFTER CORONARY BYPASS SURGERY (EAGAR)

研究表明，当绝经后妇女接受激素(雌激素)替代治疗时，她们的冠状动脉疾病比没有接受治疗的情况下要少。这项研究旨在观察，如果在3.5年内使用雌激素治疗，对患有严重冠状动脉疾病需要进行搭桥手术的女性的治疗是否会显示出较少的疾病进展或较少的新疾病发生在搭桥移植物中。这项研究的目的是确定雌激素替代疗法是否会减缓绝经后心脏病女性冠状动脉搭桥术中使用的大隐静脉移植物的狭窄进展。该网站的受试者将是30名最近接受过搭桥手术的绝经后妇女，她们没有任何搭桥手术的禁忌症。我们希望更多地了解雌激素是否可以预防未来的心脏病发作或防止未来需要进行手术。此外，有关搭桥的信息可以提供给参与者和他们的医生，这可能会改变他们正在进行的治疗。

Research studies suggest that when postmenopausal women are treated with hormone (estrogen) replacement, they have less coronary disease than if they are not. This study is designed to see whether treatment of women who have coronary disease serious enough to require bypass surgery will show less progression of disease or less new disease developing in the bypass grafts if treated with estrogen over a 3.5 year period. The purpose of the study is to determine if estrogen replacement therapy will slow the progression of narrowings in saphenous vein grafts used for coronary artery bypass surgery in postmenopausal women with heart disease. The subjects at this site will be 30 postmenopausal women who have recently undergone bypass surgery and who do not have any contraindications for bypass surgery. We hope to learn more about whether estrogen can prevent future heart attacks or prevent the need for future procedures. In addition, information about the bypass grafts can be given to the participants and their physicians, which may alter their ongoing therapy.